Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells

Tao Teng, Devin M. Ridgley, Andre Ts, Grace Y. Sun, Sholpan Askarova, James C. Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cerebral amyloid angiopathy (CAA), a condition depicting cerebrovascular accumulation of amyloid β-peptide (Aβ), is a common pathological manifestation in Alzheimer's disease (AD). In this study, we investigated the effects of Azelnidipine (ALP), a dihydropyridine calcium channel blocker known for its treatment of hypertension, on oligomeric Aβ (oAβ)-induced calcium influx and its downstream pathway in immortalized mouse cerebral endothelial cells (bEND3). We found that ALP attenuated oAβ-induced calcium influx, superoxide anion production, and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and calcium-dependent cytosolic phospholipase A2 (cPLA2). Both ALP and cPLA2 inhibitor, methylarachidonyl fluorophosphate (MAFP), suppressed oAβ-induced translocation of NFκB p65 subunit to nuclei, suggesting that cPLA2 activation and calcium influx are essential for oAβ-induced NFκB activation. In sum, our results suggest that calcium channel blocker could be a potential therapeutic strategy for suppressing oxidative stress and inflammatory responses in Aβ-stimulated microvasculature in AD.

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalACS Chemical Neuroscience
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 16 2019

Fingerprint

Endothelial cells
Amyloid
Endothelial Cells
Cytosolic Phospholipases A2
Calcium
Calcium Channel Blockers
fluorophosphate
Alzheimer Disease
Chemical activation
Cerebral Amyloid Angiopathy
Phosphorylation
Oxidative stress
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Microvessels
Superoxides
Oxidative Stress
Hypertension
azelnidipine
Therapeutics

Keywords

  • Alzheimer's
  • Amyloid-β peptide
  • Azelnidipine
  • cytosolic phospholipase A
  • endothelial cells
  • NFκB

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells. / Teng, Tao; Ridgley, Devin M.; Ts, Andre; Sun, Grace Y.; Askarova, Sholpan; Lee, James C.

In: ACS Chemical Neuroscience, Vol. 10, No. 1, 16.01.2019, p. 209-215.

Research output: Contribution to journalArticle

@article{7fcacc0f9cd548c9a9d4f50c6eca8a8f,
title = "Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells",
abstract = "Cerebral amyloid angiopathy (CAA), a condition depicting cerebrovascular accumulation of amyloid β-peptide (Aβ), is a common pathological manifestation in Alzheimer's disease (AD). In this study, we investigated the effects of Azelnidipine (ALP), a dihydropyridine calcium channel blocker known for its treatment of hypertension, on oligomeric Aβ (oAβ)-induced calcium influx and its downstream pathway in immortalized mouse cerebral endothelial cells (bEND3). We found that ALP attenuated oAβ-induced calcium influx, superoxide anion production, and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and calcium-dependent cytosolic phospholipase A2 (cPLA2). Both ALP and cPLA2 inhibitor, methylarachidonyl fluorophosphate (MAFP), suppressed oAβ-induced translocation of NFκB p65 subunit to nuclei, suggesting that cPLA2 activation and calcium influx are essential for oAβ-induced NFκB activation. In sum, our results suggest that calcium channel blocker could be a potential therapeutic strategy for suppressing oxidative stress and inflammatory responses in Aβ-stimulated microvasculature in AD.",
keywords = "Alzheimer's, Amyloid-β peptide, Azelnidipine, cytosolic phospholipase A, endothelial cells, NFκB",
author = "Tao Teng and Ridgley, {Devin M.} and Andre Ts and Sun, {Grace Y.} and Sholpan Askarova and Lee, {James C.}",
year = "2019",
month = "1",
day = "16",
doi = "10.1021/acschemneuro.8b00368",
language = "English",
volume = "10",
pages = "209--215",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells

AU - Teng, Tao

AU - Ridgley, Devin M.

AU - Ts, Andre

AU - Sun, Grace Y.

AU - Askarova, Sholpan

AU - Lee, James C.

PY - 2019/1/16

Y1 - 2019/1/16

N2 - Cerebral amyloid angiopathy (CAA), a condition depicting cerebrovascular accumulation of amyloid β-peptide (Aβ), is a common pathological manifestation in Alzheimer's disease (AD). In this study, we investigated the effects of Azelnidipine (ALP), a dihydropyridine calcium channel blocker known for its treatment of hypertension, on oligomeric Aβ (oAβ)-induced calcium influx and its downstream pathway in immortalized mouse cerebral endothelial cells (bEND3). We found that ALP attenuated oAβ-induced calcium influx, superoxide anion production, and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and calcium-dependent cytosolic phospholipase A2 (cPLA2). Both ALP and cPLA2 inhibitor, methylarachidonyl fluorophosphate (MAFP), suppressed oAβ-induced translocation of NFκB p65 subunit to nuclei, suggesting that cPLA2 activation and calcium influx are essential for oAβ-induced NFκB activation. In sum, our results suggest that calcium channel blocker could be a potential therapeutic strategy for suppressing oxidative stress and inflammatory responses in Aβ-stimulated microvasculature in AD.

AB - Cerebral amyloid angiopathy (CAA), a condition depicting cerebrovascular accumulation of amyloid β-peptide (Aβ), is a common pathological manifestation in Alzheimer's disease (AD). In this study, we investigated the effects of Azelnidipine (ALP), a dihydropyridine calcium channel blocker known for its treatment of hypertension, on oligomeric Aβ (oAβ)-induced calcium influx and its downstream pathway in immortalized mouse cerebral endothelial cells (bEND3). We found that ALP attenuated oAβ-induced calcium influx, superoxide anion production, and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and calcium-dependent cytosolic phospholipase A2 (cPLA2). Both ALP and cPLA2 inhibitor, methylarachidonyl fluorophosphate (MAFP), suppressed oAβ-induced translocation of NFκB p65 subunit to nuclei, suggesting that cPLA2 activation and calcium influx are essential for oAβ-induced NFκB activation. In sum, our results suggest that calcium channel blocker could be a potential therapeutic strategy for suppressing oxidative stress and inflammatory responses in Aβ-stimulated microvasculature in AD.

KW - Alzheimer's

KW - Amyloid-β peptide

KW - Azelnidipine

KW - cytosolic phospholipase A

KW - endothelial cells

KW - NFκB

UR - http://www.scopus.com/inward/record.url?scp=85060156901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060156901&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.8b00368

DO - 10.1021/acschemneuro.8b00368

M3 - Article

AN - SCOPUS:85060156901

VL - 10

SP - 209

EP - 215

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 1

ER -